Mixed Dyslipidemia - Pipeline Review, Q2 2011

Global Markets Direct, May 2011, Pages: 29

Mixed Dyslipidemia - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Mixed Dyslipidemia - Pipeline Review, Q2 2011', provides an overview of the Mixed Dyslipidemia therapeutic pipeline. This report provides information on the therapeutic development for Mixed Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mixed Dyslipidemia. 'Mixed Dyslipidemia - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Mixed Dyslipidemia.
- A review of the Mixed Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mixed Dyslipidemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Mixed Dyslipidemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mixed Dyslipidemia pipeline depth and focus of Mixed Dyslipidemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mixed Dyslipidemia Overview
Therapeutics Development
An Overview of Pipeline Products for Mixed Dyslipidemia
Mixed Dyslipidemia Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Mixed Dyslipidemia Therapeutics - Products under Development by Companies
Companies Involved in Mixed Dyslipidemia Therapeutics Development
Abbott Laboratories
Merck & Co., Inc.
Mixed Dyslipidemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
MK-0524A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0524B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Certriad - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NanoActive Rosuvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mixed Dyslipidemia Therapeutics – Drug Profile Updates
Mixed Dyslipidemia Therapeutics - Discontinued Products
Mixed Dyslipidemia - Featured News
Apr 18, 2011: Amarin's AMR101 Phase III ANCHOR Trial Meets All Primary And Secondary Endpoints
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Mixed Dyslipidemia, Q2 2011
Products under Development for Mixed Dyslipidemia – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Abbott Laboratories, 2011
Merck & Co., Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Mixed Dyslipidemia Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Mixed Dyslipidemia, Q2 2011
Products under Development for Mixed Dyslipidemia – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Late Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Global Dyslipidemia Drug Pipeline Capsule - 2012
• Epidemiology: Dyslipidemia - Undertreated and underdiagnosed pandemic
• Dyslipidemia (Event Driven)
• Market and Product Forecasts: Antidyslipidemics - Set for the impact of generic Lipitor
• Epidemiology: Dyslipidemia
• The Pricing and Reimbursement Environment for Metabolic Disease Therapies
• PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013
• Nausea – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013